Even granting that this is a challenging time for the orthopedics industry (and healthcare device providers in general), Smith & Nephew (NYSE:SNN) is struggling a little more than most. The company has been losing share in orthopedic implants like hips and knees and disappointing investors with regards to cash flow production, and the stock has been chopping around in a $20 range for about three years now. While the news on November 28 of the company's Healthpoint Biotherapeutics acquisition does bring in advanced wound care products with very good growth, Smith & Nephew is having to pay a pretty hefty price for this growth injection and this just isn't a sustainable long-term plan.

Guide To Oil And Gas Plays: We've got your comprehensive guide to oil and gas shales in North America.

Buying a Good Product That Most People Haven't Heard of
Wound care is not an especially well-appreciated segment of the healthcare market, so it's altogether understandable if most investors aren't familiar with "bioactive wound healing" or Healthpoint Biotherapeutics. Nevertheless, Smith & Nephew will be paying $782 million in cash to acquire Healthpoint and its portfolio of products build around bioactive debridement, dermal repair and wound regeneration.

The principle asset of Healthpoint is Collagenase Santyl pointment, an enzymatic debrider for dermal ulcers and burns. This product alone makes up about three-quarters of Healthpoint's sales and has been growing quite well for the company. Other products of note include Oasis for leg ulcers and Regranex for diabetic foot ulcers. Healthpoint also had a product in Phase 3 studies (HP802-247) for venous leg ulcers.

Smith & Nephew indicated that Healthpoint was on target for $190 million in sales this year, up about 25% from last year. While the company provided less information on recent margins, it seems as though Healthpoint is not strongly profitable at this point - though due at least in part to a lack of scale.

SEE: Analyzing An Acquisition Announcement

It's Logical to Get Bigger Here
With about 90% of Healthpoint's sales in the United States, this will double the company's U.S. wound care business, and grow the overall wound care business by about 20%. That will elevate wound care to about 30% of the total, so orthopedics will still be a significant part of the story post-deal.

Expanding the wound care business makes plenty of sense for Smith & Nephew. For starters, while Kinetic Concepts and Smith & Nephew have both faced challenging reimbursement decisions in wound care, it's not a market with a significant elective procedure component. What's more, it's also a market still in need of (and willing to pay for) better technology and better outcomes - persistent wounds/ulcers are a major problem for patients with limited mobility, and particularly those with diabetes.

This also happens to be a market where Smith & Nephew has scale and influence. This deal will significantly close the gap with Kinetic Concepts in terms of overall market share, and should give the company a meaningful boost in bioactive wound healing - one of the strongest growth segments in the market. Together, these two companies will have close to 50% share, with 3M (NYSE:MMM) and Convatec a ways back. What's more, this is not an easy buy ((Johnson & Johnson (NYSE:JNJ) largely exited professional wound care in 2008)), but it is one that I believe is still worthwhile and can reward a disciplined player with scale.

It's also worth noting that Smith & Nephew isn't getting anywhere fast in orthopedics. While companies like Johnson & Johnson, Zimmer (NYSE:ZMH) and Stryker (NYSE:SYK) generally saw about a 2% growth in their reconstruction businesses (hips and knees) in the third quarter, Smith & Nephew saw a 2% decline, with particular weakness in hips. Now some of this can be tied to Smith & Nephew's greater exposure to Europe (where reimbursement pressures are more intense), but it can also be tied to the fact that Smith & Nephew's products are longer in the tooth and the company has not been as innovative as its rivals.

SEE: 5 Must-Have Metrics For Value Investors

The Bottom Line
Although I like the Healthpoint deal, paying more than four times sales makes for an expensive deal these days ((though not out of line given what Shire (Nasdaq:SHPG) paid for Advanced BioHealing in 2011)). Healthpoint is a good enough asset to be worth this price, but the point stands that Smith & Nephew needs to step up its R&D/innovation game, as it cannot afford to keep buying growth at this sort of multiple.

Though I think the deal is a good one for Smith & Nephew, it doesn't change my feeling that this is a stock better left out of investors' portfolios. There are too many quality names out there ((like Medtronic (NYSE:MDT) and Covidien (NYSE:COV)) to go with Smith & Nephew instead, and if investors want to take some risk and invest in companies that need to improve their execution, St. Jude (NYSE:STJ) and Stryker look like better candidates for that sort of move.

At the time of writing, Stephen D. Simpson has owned shares of 3M since 2007.

Related Articles
  1. Investing

    The ABCs of Bond ETF Distributions

    How do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
  2. Stock Analysis

    The 5 Best Dividend Stocks in the Healthcare Sector

    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash flows to afford high payouts.
  3. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  4. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  5. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  6. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  7. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  8. Mutual Funds & ETFs

    The 4 Best Buy-and-Hold ETFs

    Explore detailed analyses of the top buy-and-hold exchange traded funds, and learn about their characteristics, statistics and suitability.
  9. Mutual Funds & ETFs

    Top 5 Health Mutual Funds

    Learn about the top five mutual funds that invest in stocks of companies that primarily operate in the health care sector of the United States.
  10. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. What role does the agency problem play in the modern Health Care industry?

    Agency problems vary from health care system to health care system, and not all economists agree on the degree and desirability ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  6. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!